Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection

  1. Kleper N.F. de Almeida, MD; and
  2. Larry M. Bush, MD
  1. From JFK Medical Center, Atlantis, FL 33462.

    TO THE EDITOR:

    We were delighted to read the article by King and associates (1) on the emergence of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) USA 300 clone as the predominant cause of community-onset S. aureus skin and soft-tissue infections in the Atlanta, Georgia, area. However, we disagree with the authors' statement that “the efficacy of nonglycopeptide antimicrobial agents in treating MRSA skin and soft-tissue infections remains incompletely defined, and clinical trials are needed to better define their role.” Despite …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med August 1, 2006 vol. 145 no. 3 231-232
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 1, 2009, 151 (11)
    1. Alert me to current issues